FMT

Researchers discovered a group of bacterial species and strains that may be used as an alternative to fecal microbiota transplantation to restore a patient’s gut microbiome, according to a study in Nature Microbiology. “This study is another step in the evolution of FMT. The field is moving away from FMT and toward defined consortium of microbes that can restore a function of the gut

Healthcare providers' knowledge of FMT is relatively low and education is an effective strategy to improve it. As knowledge of FMT increases, willingness to recommend it also increases. Strengthening FMT clinical efficacy and reducing infection can enhance its public acceptance, application and popu …

(2021). Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report. Current Medical Research and Opinion. Ahead of Print.

At this time, fecal transplant procedures are used almost exclusively to treat Clostridioides difficile, or C. diff, a bacterium that causes severe and sometimes life-threatening diarrhea and colitis.

Objective: This study aimed to investigate the long-term efficacy of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS).Study Methods: In this single-center long-term follow-up study, FMT treatment was administered to patients with moderate to severe IBS (IBS severity scoring system (IBS-SSS) > 175). After 1 year of treatment, it was decided whether to repeat FMT based on IBS-SSS score (IBS-SSS > 175). Baseline characteristics before and after FMT and questionnaires were completed at 1, 3, 6, 12, 24, 36, 48, and 60 months after FMT. The study outcomes included treatment efficacy rates, change of IBS-SSS, IBS-specific quality of life and fatigue, effect on stool frequency, Bristol Stool Scale for IBS-C and IBS-D, and side effects.Results: A total of 227 patients (47.58% IBS-C, 39.21% IBS-D, and 13.22% IBS-M) were recruited (142 females and 85 males with a mean age of 41.89 ± 13.57 years). The efficacy rates were 108 (51.92%), 147 (74.62%), 125 (74.41 %), 88 (71.54%), 78 (75.00%), 65 (73.03%), 45 (61.64%), and 37 (62.71%) at different follow-up time points. The total IBS-SSS score was 321.37 ± 73.89 before FMT, which significantly decreased after 1 month. The IBS-specific quality of life (IBS-QoL) score was 40.24 ± 11.34 before FMT, increased gradually, and was significantly higher at 3 months compared to before FMT. The total Fatigue Assessment Scale (FAS) score was 47 ± 8.64 before FMT and was significantly lower at 3 months. During foll...

Patients with multiple recurrent Clostridioides difficile infection (rCDI) have a disturbed gut microbiota that can be restored by fecal microbiota tr…

Clostridioides (previously Clostridium) difficile infection (CDI) is a common cause of antibiotic-associated diarrhea, whose symptoms range from mild diarrhea to life-threatening pseudomembranous colitis. CDI is characterized by significant recurrence rate following initial resolution and recurrent …

Alzheimer’s disease (AD), the most common form of dementia, is a leading cause of death and a major cause of morbidity in older people. The disease is character...

Food and Drug Administration (FDA) safety alert in 2019 reported transmission of a multidrug resistant organism from FMT donor to recipient resulting in the death of 1 patient. Secondly, the coronavirus disease 2019 (COVID-19) pandemic induced further safety and regulatory challenges. Biotherapeutics are promising and more readily regulated treatment options for rCDI, which may replace FMT in the near future for adults upon regulatory agency approvals. Such approvals, however, are expected to be significantly delayed for children, raising concerns for limited access to effective treatment for children with rCDI. In this commentary, we discuss the recent challenges and future directions of FMT and microbial therapeutics in children with rCDI....

When antibiotics kill off too many "good" bacteria in the digestive tract during treatment of C. Diff, Fecal Microbial Transplants can help replenish bacterial balance. For more information: http://www.hopkinsmedicine.org/gastroenterology_hepatology/clinical_services/advanced_endoscopy/fecal_transplantation.html

Ann Ist Super Sanita. 2021 Jul-Sep;57(3):239-243. doi: 10.4415/ANN_21_03_07.ABSTRACTClostridioides (previously Clostridium) difficile infection (CDI) is a

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

FMT treatment was less effective for primary C difficile infections.

AbstractBackground. We evaluated whether integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remissio

Background: Faecal microbiota transplantation (FMT) is an effective treatment of recurrent Clostridioides difficile infection (rCDI) and is being applied experi...

💩#FMT did not induce remission (in fact, some got worse)🥑#diet led to improvement in 40% overall, but disease severity impacted response 🔴0/17 in SCCAI ≥9 🔴1/28 biologic refractory patients 🟠 12/34 (35.3%) in SCCAI

The vast majority of #FMT studies failed to address core methodological aspectsWe recommend GutAlive®, a unique anaerobic stool collection device that - Ensure #anaerobicconditions from sample collection and transportation- Normalizes standardization for FMT protocols https://t.co/KsFzhhwooC— Microviable Therapeutics (@microviable) September 16, 2021

In a fecal microbiota transplant (FMT) a donor’s fecal matter is transferred to a patient's colon. Healthy microbes may control infections.

Phase 3 study results show that a microbiome therapeutic consisting of purified Firmicutes spores reduced the risk for recurrent Clostridioides difficile infection (rCDI) by 59% compared with placebo six months after treatment for a prior CDI.   

An Overview of Fecal Microbiota Transplantation for C. difficile📽️ Full interview with Paul Feuerstadt, MD, FACG, AGAF available on PracticeUpdate - https://t.co/egNQzLC97o@DrPaulGastro #CDiff pic.twitter.com/jg2GqXa33j— PracticeUpdate (@practiceupdate) September 15, 2021

A review of the key developments during the year in #FMT. Thanks to @HoldGeorgina for the invitation and to @bhmullish and #jamesalexander for their heavy lifting. https://t.co/NucMuBcoEU— Jonathan Segal (@Jonathansegal85) September 9, 2021

Gary Wu, MD @penngihep provides a High Impact review on the Human MICROBIOME in Health & Disease! #FMT has been impacted by the #Covid19 pandemic.#DIY discouraged due to potential for infectious transmission & longitudinal risk unknownFuture therapeutic timeline PROMISING! pic.twitter.com/6eZzxJJEih— Neilanjan Nandi, MD, FACP (@FITWITMD) September 11, 2021

There's growing demand for healthy feces from human donors to treat C. difficile and other conditions

We show that FMT is strongly associated with a decrease in CDI recurrence compared with the usual care with generally mild complications for up to 2 years.

Both formulations demonstrated robust immunogenicity. Both studies stopped early due to grade 3 injection site redness postdose 2 of the day regimen; neither formulation progressed to later stage development. Instead, an aluminum hydroxide-containing formulation of the vaccine candidate administered …

Transfer of faecal material through capsules in the treatment of various diseases. Evidence for clinical efficacy The bacteria and other microorganisms of the gut is different in patient with various diseases in comparison with healthy subjects.Therefore, ways to change the microorganisms of …

Dr David Ong on setting up of SEA first stool bank--AMILI. @IDDF_CUHK#GITwitter #microbiome #fmt #iddf2021 #probiotics @DrCalvinKoh @jonathanlwj @DrMarkMuthiah @fan_kristie @DrHuangDQ @SengGeeLim1 #nuhgastro pic.twitter.com/XJbJmd1lGl— Kewin Siah (@KewinSiah) September 4, 2021